Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Myocardial Ischemia Pipeline Review, H2 2016 - Therapeutics Report Details 10 Companies & 20 Molecules - Research and Markets

Research and Markets
Posted on: 10 Oct 16

Research and Markets has announced the addition of the "Myocardial Ischemia - Pipeline Review, H2 2016" report to their offering.

Myocardial Ischemia pipeline therapeutics constitutes close to 20 molecules, out of which approximately 17 molecules are developed by Companies and the remaining by Universities/Institutes. The molecules developed by Companies in Phase III, Phase I and Preclinical stages are 3, 1 and 13, respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocardial Ischemia lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses.

The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Myocardial Ischemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Myocardial Ischemia Overview
  3. Therapeutics Development
  4. Pipeline Products for Myocardial Ischemia - Overview
  5. Pipeline Products for Myocardial Ischemia - Comparative Analysis
  6. Myocardial Ischemia - Therapeutics under Development by Companies
  7. Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes
  8. Myocardial Ischemia Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Myocardial Ischemia - Products under Development by Companies
  13. Myocardial Ischemia - Products under Investigation by Universities/Institutes
  14. Myocardial Ischemia - Companies Involved in Therapeutics Development
  • Bayer AG
  • Cellmid Limited
  • CohBar Inc.
  • Lixte Biotechnology Holdings Inc.
  • Miltenyi Biotec GmbH
  • NoNO Inc.
  • Shire Plc
  • Symic Biomedical Inc.
  • Taxus Cardium Pharmaceuticals Group Inc.
  • ViroMed Co. Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 10/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.